Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Underidentification and undertreatment issues.

Michael B Bottorff1

  • 1University of Cincinnati College of Pharmacy, 3223 Eden Ave. Loc #4, Cincinnati, OH 45267-0004, USA. Michael.Bottorff@UC.edu

Journal of Managed Care Pharmacy : JMCP
|November 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Response to: Letter to the Editor Regarding "Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review".

Advances in therapy·2020
Same author

Practical Insight Into Anticoagulation for an Aging Population.

The Senior care pharmacist·2020
Same author

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.

Advances in therapy·2020
Same author

Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.

Pharmacotherapy·2017
Same author

The relationship between four health-related quality-of-life indicators and use of mammography and Pap test screening in US women.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2015
Same author

Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.

Journal of managed care & specialty pharmacy·2015
Same journal

Should eligibility for medication therapy management be based on drug adherence?

Journal of managed care pharmacy : JMCP·2014
Same journal

Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden.

Journal of managed care pharmacy : JMCP·2014
Same journal

Pharmacists' role in the care of patients with heart failure: review and future evolution.

Journal of managed care pharmacy : JMCP·2014
Same journal

PCMHs, ACOs, and medication management: lessons learned from early research partnerships.

Journal of managed care pharmacy : JMCP·2014
Same journal

Adherence to national recommendations for safe methotrexate dispensing in community pharmacies.

Journal of managed care pharmacy : JMCP·2014
Same journal

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Journal of managed care pharmacy : JMCP·2014
See all related articles

Despite guidelines, many patients with high cholesterol remain undiagnosed or undertreated, failing to reach treatment goals. Improving dyslipidemia diagnosis and treatment is crucial for reducing coronary heart disease (CHD) risk.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Coronary heart disease (CHD) is a major cause of morbidity and mortality.
  • Adult Treatment Panel (ATP) guidelines recommend cholesterol reduction for CHD risk management.
  • Despite evidence, significant gaps exist in dyslipidemia diagnosis and treatment.

Purpose of the Study:

  • To highlight the challenges in diagnosing and treating dyslipidemia.
  • To emphasize the need for improved adherence to cholesterol management guidelines.
  • To underscore the importance of achieving therapeutic targets for low-density lipoprotein cholesterol (LDL-C).

Main Methods:

  • Review of Adult Treatment Panel (ATP) guidelines and related data.
  • Analysis of patient eligibility for lipid modification.

Related Experiment Videos

  • Examination of current diagnosis, treatment, and persistence rates for dyslipidemia.

    • Main Results:

    • Over 65 million Americans are eligible for lipid modification.
    • Approximately 50% of patients do not have cholesterol assessed.
    • Less than 45% receive lipid-modifying therapy, and over 75% fail to reach LDL-C goals.
    • Fewer than 30% persist with therapy beyond one year.

    Conclusions:

    • Current diagnosis and treatment rates for dyslipidemia are insufficient to reduce CHD risk.
    • Improved detection and adherence to therapeutic targets are necessary.
    • Addressing treatment persistence is critical for effective CHD prevention.